Clinical Study

Diagnosis of Distal Cholangiocarcinoma after the Removal of Choledocholithiasis

Yasuhiro Ito, Takeshi Kenmochi, Tomohisa Egawa, Shinobu Hayashi, Atsushi Nagashima, and Yuko Kitagawa

1 Department of Surgery, Saiseikai Yokohamashi Tobu Hospital, 3-6-1 Shimosueyoshi, Tsurumi-ku, Yokohama-shi, Kanagawa 230-8765, Japan
2 Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan

Correspondence should be addressed to Yasuhiro Ito, yasuito@ca3.so-net.ne.jp

Received 6 August 2012; Revised 16 October 2012; Accepted 18 October 2012

1. Introduction

The frequency of cholangiocarcinoma is increasing globally, and it currently accounts for 3% of all gastrointestinal cancers [1]. The 5-year survival rates of patients with perihilar and distal tumors have been reported to be 10% and 23%, respectively [2]. Early cholangiocarcinoma is difficult to diagnose because the symptoms usually occur late in the disease. Because these tumors tend to invade the surrounding vessels and nerves, most patients have unresectable disease at diagnosis and poor survival. The prognosis remains unsatisfactory even if the patient undergoes extensive surgery, which is the only curative treatment for these tumors. Therefore, early detection and diagnosis are needed to improve long-term survival. Reports of distal cholangiocarcinoma associated with choledocholithiasis are very rare, and the causal relationship is not established despite the fact that intrahepatic cholangiocarcinoma is a risk factor associated with hepatolithiasis. In this study, we retrospectively analyzed cases of patients with distal cholangiocarcinoma diagnosed after the removal of choledocholithiasis.

2. Patients and Methods

2.1. Patients. Cholangiocarcinoma is anatomically classified as intrahepatic or extrahepatic. Extrahepatic cholangiocarcinoma is classified as either perihilar or distal tumors according to the distance from the cystic ducts. This was a retrospective study of 46 patients with distal cholangiocarcinoma who underwent surgical treatment between April 2007 and December 2011. We assigned 9 cases of cholangiocarcinoma with choledocholithiasis to Group A; these cases accounted for 2.9% of all patients treated endoscopically for choledocholithiasis at our institution. As a control group,
37 patients with cholangiocarcinoma who did not undergo choledocholithiasis resection during the same period were assigned to Group B. Clinical features, endoscopic retrograde cholangiopancreatography (ERCP) findings, and histological diagnoses were analyzed retrospectively. Final pathological reports were reviewed to confirm the diagnosis of distal cholangiocarcinoma. The diameter of the distal bile duct and the morphology of the bile duct narrowing were also analyzed using the ERCP images.

2.2. Endoscopic Treatment. All patients with choledocholithiasis diagnosed by radiological visualization (ultrasonography (US), computed tomography (CT), magnetic resonance cholangiopancreatography) underwent endoscopic removal of bile duct stones. After stone removal, cholangiography was performed to confirm the complete removal of choledocholithiasis. Occasionally, owing to some limitations in the detection of small stones and sludge, they were not detected by cholangiography. Therefore, we performed intraductal US (IDUS) for a case because of residuals.

2.3. Surgical Procedure. Patients with distal tumors generally underwent pancreaticoduodenectomy with or without preservation of the pylorus. All patients underwent dissection of the regional lymph nodes, except for the para-aortic lymph nodes.

2.4. Data Collection. Preoperative demographic and clinical data and pathologic diagnosis data were collected prospectively.

2.5. Statistical Analysis. Continuous data were expressed as mean ± standard deviation (SD). The χ2 test was used to compare qualitative parameters, and the Student t-test was used for quantitative parameters. P values of < 0.05 were considered significant.

3. Results

3.1. Patient Characteristics. Three hundred and eleven patients who were diagnosed with choledocholithiasis between April 2007 and December 2011 underwent ERCP at our institution. Nine of them (2.9%) were diagnosed with distal cholangiocarcinoma by ERCP or IDUS after stone removal despite the tumors not being detected by radiological visualization. There were no statistical differences between the patient groups regarding age or gender. The only significant difference between Group A and Group B (P = 0.001) was in terms of abdominal pain at admission, and other clinical presentations were similar between both groups. All patients in Group A had gall bladder stones, compared with 7 patients (19%) in Group B (P < 0.01) (Table 1). The clinicopathological findings for Group A are summarized in Table 2.

3.2. Radiological Findings. The diagnostic imaging test results are shown in Table 3. In 7 patients in Group A, US detected no tumor in 3 patients (43%) and a dilatation of the bile duct in 4 patients (57%). In 34 patients in Group B, US detected no tumor in 7 patients (21%), a dilatation of the bile duct in 12 patients (35%), and a tumor in 15 patients (44%) (P = 0.083). Of the 9 patients in Group A, CT detected no tumor in 6 patients (67%) and a dilatation of the bile duct in 3 patients (33%). In 35 patients in Group B, CT detected no tumor in 6 patients (17%), a dilatation of the bile duct in 9 patients (26%), and a tumor in 20 patients (57%) (P = 0.003). Of the 9 patients in Group A, ERCP detected normality in 2 patients (22%) and abnormalities in 7 patients (78%). Of the 32 patients in Group B, ERCP detected normality in 4 patients (13%) and abnormalities in 28 patients (88%) (P = 0.597). IDUS detected a tumor in 8 patients in Group A, while in Group B, IDUS detected normality in 1 patient (3%) and tumors in 29 patients (97%) (P = 1.000).

3.3. Endoscopic Retrograde Cholangiopancreatography Findings. A significant difference was observed in the diameter of the common bile duct between the 2 groups (P = 0.043). The morphology of bile duct narrowing was classified as normal or mild irregularity, unilateral narrowing, or bilateral narrowing. The bile duct morphologies in the Group A patients were normal or mild irregularity in 3 patients (33%), unilateral narrowing in 5 patients (56%), and bilateral narrowing in 1 patient (11%). Of the Group B patients, 5 (14%) presented with normal or mild irregularity, 12 (32%) with unilateral narrowing, and 20 (54%) with bilateral narrowing (Table 4).

3.4. Histological Findings. Tumor size was not significantly different between the groups. The histological type of the distal cholangiocarcinoma in all (100%) Group A patients (9 patients in total) was well-differentiated adenocarcinoma. In Group B patients, the histological types of the distal cholangiocarcinoma were papillary adenocarcinomas in 3 patients (8%), well-differentiated adenocarcinoma in 20 patients (54%), moderately differentiated adenocarcinoma in 2 patients (5%), and undifferentiated carcinoma in 1 patient (3%).
Table 2: Summary of the clinicopathological findings of Group A.

| Case | Age | Gender | Clinical presentation           | Cholangiographic finding | Differentiation | Depth | Prognosis (months) |
|------|-----|--------|---------------------------------|--------------------------|-----------------|-------|--------------------|
| 1    | 60  | Male   | Jaundice, abdominal pain, fever | Unilateral narrowing     | well            | m     | 11                 |
| 2    | 74  | Male   | Asymptomatic                    | Unilateral narrowing     | well            | m     | Alive              |
| 3    | 79  | Female | Asymptomatic                    | Bilateral narrowing      | well            | m     | 5                  |
| 4    | 62  | Female | Abdominal pain                  | Normal                   | well            | m     | 3                  |
| 5    | 61  | Female | Jaundice, abdominal pain        | Normal                   | well            | m     | 3                  |
| 6    | 59  | Male   | Jaundice, abdominal pain        | Unilateral narrowing     | well            | fm    | 45                 |
| 7    | 84  | Female | Jaundice, abdominal pain        | Unilateral narrowing     | well            | fm    | 2                  |
| 8    | 74  | Male   | Jaundice, abdominal pain, fever | Unilateral narrowing     | well            | ss    | 60                 |
| 9    | 66  | Female | Jaundice, abdominal pain        | Mild irregularity         | well            | se    | 81                 |

m: mucosa, fm: fibromuscular layer, ss: subserous layer, se: serosa.

Table 3: Radiologic findings.

| US              | Group A | Group B | P value |
|-----------------|---------|---------|---------|
| Normal          | 3       | 7       | 0.083   |
| Dilatation      | 4       | 12      |         |
| Tumor           | 0       | 15      |         |
| CT              |         |         |         |
| Normal          | 6       | 6       | 0.003   |
| Dilatation      | 3       | 9       |         |
| Tumor           | 0       | 20      |         |
| ERCP            |         |         |         |
| Normality       | 2       | 4       | 0.597   |
| Abnormality     | 7       | 28      |         |
| IDUS            |         |         |         |
| Normality       | 0       | 1       | 1.000   |
| Tumor           | 8       | 29      |         |

Table 4: Endoscopic retrograde cholangiopancreatography findings.

| Group A | Group B | P value |
|---------|---------|---------|
| n = 9     | n = 37   |         |
| Diameter of the common bile duct | 9.7 ± 2.1 | 13.0 ± 4.7 | 0.043 |
| Morphology of the bile duct |         |         | 0.061 |
| Normal or mild irregularity | 3       | 5       |         |
| Unilateral narrowing | 5       | 12      |         |
| Bilateral narrowing | 1       | 20      |         |

Table 5: Histological findings.

| Group A | Group B | P value |
|---------|---------|---------|
| n = 9     | n = 37   |         |
| Tumor size | 15.3 ± 9.7 | 24.6 ± 14.1 | 0.081 |
| Depth of invasion |         |         |         |
| Mucosa | 5       | 7       | 1.130   |
| Fibromuscular layer | 2       | 5       |         |
| Subserous layer | 1       | 9       |         |
| Serosa | 1       | 7       |         |
| Serosa infiltrating |         |         |         |
| Subserous layer—deeper | 2 (22%) | 25 (68%) | 0.022 |
| Differentiation |         |         |         |
| Papillary | 0       | 3       | 0.087   |
| Well | 9       | 20      |         |
| Moderately | 0       | 11      |         |
| Poorly | 0       | 3       |         |
| Lymph node involvement | 1       | 13      | 0.240   |

in 11 patients (30%), and poorly differentiated adenocarcinoma in 3 patients (8%). In Group A, the depth of invasion reached the mucosa in 5 patients (56%), the fibromuscular layer in 2 patients (22%), the subserous layer in 1 patient (11%), and the serosa in 1 patient (11%). In Group B, the depth of invasion reached the mucosa in 7 patients (19%), the fibromuscular layer in 5 patients (14%), the subserous layer in 9 patients (24%), the serosa in 7 patients (19%), and the serosal infiltration in 9 patients (24%). In 7 patients (78%) in Group A, the cholangiocarcinoma invaded the mucosa and the fibromuscular layer at an early stage. The cholangiocarcinoma invaded the subserous layer: invaded the serosa in 22% of the patients (2/9) and infiltrated the serosa in 68% of the patients (25/37) (P = 0.022). In Group A, lymph node classification was absent in 8 patients (89%) and present in 1 patient (11%). In Group B, the lymph node classification was absent in 24 patients (65%) and present in 13 patients (35%) (P = 0.234) (Table 5).

3.5. Prognoses. All patients in Group A were alive. In Group B, the median survival time was 46 months. Survival time was not significantly different between the 2 groups (P = 0.126). Furthermore, survival time was not influenced by the existence of choledocholithiasis.

4. Discussion

Because most patients with cholangiocarcinoma tend to invade the surrounding vessels and nerves, they are unresectable at the time of diagnosis, and consequently patient survival is poor. Early detection and diagnosis are essential
for improving long-term survival because the 5-year survival rates of patients with distal cholangiocarcinoma have been reported to be 23% [2]. Ekbom et al. [3] reported that gall bladder stones are a probable risk factor for extrahepatic bile duct cancer. However, choledocholithiasis has not been reported as a cause of extrahepatic cholangiocarcinoma to date. Reports of distal cholangiocarcinoma associated with choledocholithiasis are very rare, and the causal relationship remains to be established. Because we observed early distal cholangiocarcinoma after stone removal, we investigated the probable role of choledocholithiasis as a risk factor. Kimura et al. [4] described the relationship between extrahepatic bile duct carcinoma and stones in autopsy cases. Extrahepatic bile duct carcinomas were present in 7 of 143 patients (4.9%) with stones, which was significantly higher than the rate in the patients without stones (26 of 4339; 0.6%) (P < 0.01). Nishimura et al. [5] also reported the relationship between distal cholangiocarcinoma and choledocholithiasis. The incidence of intrahepatic choledocholithiasis associated with hepatocholangitis as a risk factor has been reported to be 2.4–5.4% [6–8]. Chronic inflammation, biliary infection, and cholestasis due to hepatocholangitis lead to cholangiocarcinoma as a result of chronic inflammation in the biliary epithelium. Furthermore, Terada and Nakanuma reported that carcinogenesis in biliary epithelium in livers with stones was a multistep process involving hyperplasia, dysplasia, and adenocarcinoma [9]. We considered the possibility that stones may also be associated with distal cholangiocarcinoma as well as being a risk factor for intrahepatic cholangiocarcinoma. In the present study, in 1 case of stone impaction, we found that the tumor was located proximal to the stone. Because all the other tumors were distal to the stones, persistent chronic stimulation by stones rather than cholestasis and infection may lead to carcinogenesis in the biliary epithelium.

The recurrence rate of choledocholithiasis after stone removal has been reported to be 24% [10–12]. Therefore, it is possible that a cholangiogram obtained immediately after stone removal underestimates residual stones owing to numerous air bubbles entering the bile duct from the sphincterotomy. IDUS after stone removal showed residual stones in 33–40% of cases [13, 14], although cholangiography did not detect them. Therefore, IDUS after stone removal is useful because the sensitivity of IDUS for detecting choledocholithiasis is also very high [15]. In addition, a prospective study for the utility of IDUS has been reported [16]. Additional IDUS to confirm complete stone clearance decreases the early recurrence rate of choledocholithiasis. For example, the recurrence rate was 13.2% in the non-IDUS group and 3.4% in the IDUS group (P < 0.05), and multivariate analysis identified additional IDUS as an independent risk factor for the recurrence of bile duct stones. Three hundred and eleven consecutive patients who underwent ERCP for choledocholithiasis between April 2005 and December 2011 were included in the study. All patients underwent IDUS after stone removal. Fortunately, IDUS detected biliary strictures in 2.9% of cases (9/311) that were pathologically diagnosed as cholangiocarcinoma. In each case, IDUS initially detected a cholangiocarcinoma in the absence of a mass on CT or magnetic resonance imaging. Because the early distal cholangiocarcinomas in 39% of cases (7/18) in our institution were associated with choledocholithiasis, we suggest that choledocholithiasis shows an etiologic association with cholangiocarcinoma. IDUS is very useful for evaluating not only residual stones but also biliary strictures [17, 18]. Because IDUS can be performed easily and safely over a guidewire, we performed routine additional IDUS with ERCP in all cases. In this study, ERCP and IDUS in Group A detected biliary strictures without tumor lesions on US or CT in 7 of 9 cases and all cases, respectively. Because additional IDUS may underestimate the coexistence of cholangiocarcinoma after stone removal, it should be performed carefully.

In another study, histological grading indicated that the cholangiocarcinoma in a group of hepatolithiasis patients exhibited a significantly higher percentage of well-differentiated tumors [19]. Because all cases of cholangiocarcinoma associated with choledocholithiasis were pathologically diagnosed as well differentiated, the result of this study is similar to that of our study. Chronic stimulation of biliary epithelium by stones may be associated with well-differentiated cholangiocarcinoma. It has been hypothesized that carcinogenesis in the biliary epithelium in livers with hepatolithiasis is a multistep process that follows a hyperplasia-dysplasia-carcinoma sequence [9, 20, 21]. In a study on the carcinogenic process in patients with cholangiocarcinoma arising from pancreaticobiliary dysfunction, it was hypothesized that carcinogenesis is involved in chronic inflammation in the biliary epithelium and genetic abnormalities in K-ras, p53, MUC1, and COX2 occurred after chronic inflammation [22, 23].

In conclusion, IDUS after stone removal may potentially help in the detection of unexpected tumors. Therefore, we believe that IDUS after stone removal will lead to improve outcome and prognosis. We also hope that this study will assist in the understanding of both distal cholangiocarcinoma associated with choledocholithiasis and the molecular mechanisms underlying choledocholithiasis-related distal cholangiocarcinoma, for which only limited data are available. However, further studies with a higher number of cases are required to support the findings presented here.

References

[1] J. N. Vauthey and L. H. Blumgart, “Recent advances in the management of cholangiocarcinomas,” Seminars in Liver Disease, vol. 14, no. 2, pp. 109–114, 1994.

[2] M. L. DeOliveira, S. C. Cunningham, J. L. Cameron et al., “Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution,” Annals of Surgery, vol. 245, no. 5, pp. 755–762, 2007.

[3] A. Ekbom, C. C. Hsieh, J. Yuen et al., “Risk of extrahepatic bile duct cancer after cholecystectomy,” The Lancet, vol. 342, no. 8882, pp. 1262–1265, 1993.

[4] W. Kimura, H. Shimada, A. Kuroda, and Y. Morioka, “Carcinoma of the gallbladder and extrahepatic bile duct in autopsy cases of the aged, with special reference to its relationship to gallstones,” American Journal of Gastroenterology, vol. 84, no. 4, pp. 386–390, 1989.
[5] M. Nishimura, S. Naka, K. Hanazawa et al., “Cholangiocarcinoma in the distal bile duct: a probable etiologic association with choledocholithiasis,” *Digestive Diseases and Sciences*, vol. 50, no. 11, pp. 2153–2158, 2005.

[6] M. E. Chen, Y. Y. Jan, C. S. Wang, L. B. B. Jeng, T. L. Hwang, and S. C. Chen, “Intrahepatic stones associated with cholangiocarcinoma,” *American Journal of Gastroenterology*, vol. 84, no. 4, pp. 391–395, 1989.

[7] S. M. Sheen-Chen, F. F. Chou, and H. L. Eng, “Intrahepatic cholangiocarcinoma in hepatolithiasis: a frequently overlooked disease,” *Journal of Surgical Oncology*, vol. 14, no. 4, pp. 131–135, 1991.

[8] Y. M. Zhou, Z. F. Yin, J. M. Yang et al., “Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China,” *World Journal of Gastroenterology*, vol. 14, no. 4, pp. 632–635, 2008.

[9] T. Terada and Y. Nakanuma, “Cell kinetic analyses and expression of carcinoembryonic antigen, carbohydrate antigen 19-9 and DU-PAN-2 in hyperplastic, pre-neoplastic and neoplastic lesions of intrahepatic bile ducts in livers with hepatoliths,” *Virchows Archiv—A Pathological Anatomy and Histopathology*, vol. 420, no. 4, pp. 327–335, 1992.

[10] M. L. Freeman, D. B. Nelson, S. Sherman et al., “Complications of endoscopic biliary sphincterotomy,” *The New England Journal of Medicine*, vol. 335, no. 13, pp. 909–918, 1996.

[11] F. Prat, N. A. Malak, G. Pelletier et al., “Biliary symptoms and complications more than 8 years after endoscopic sphincterotomy for choledocholithiasis,” *Gastroenterology*, vol. 110, no. 3, pp. 894–899, 1996.

[12] R. H. Hawes, P. B. Cotton, and A. G. Vallon, “Follow-up 6 to 11 years after duodenoscopic sphincterotomy for stones in patients with prior cholecystectomy,” *Gastroenterology*, vol. 98, no. 4, pp. 1008–1012, 1990.

[13] T. L. Ang, E. K. Teo, K. M. Fock, and J. Y. Lyn Tan, “Are there roles for intraductal US and saline solution irrigation in ensuring complete clearance of common bile duct stones?” *Gastrointestinal Endoscopy*, vol. 69, no. 7, pp. 1276–1281, 2009.

[14] A. Ohashi, N. Ueno, K. Tamada et al., “Assessment of residual bile duct stones with use of intraductal US during endoscopic balloon sphincteroplasty: comparison with balloon cholangiography,” *Gastrointestinal Endoscopy*, vol. 49, no. 3, part 1, pp. 328–333, 1999.

[15] J. H. Moon, Y. D. Cho, S. W. Cha et al., “The detection of bile duct stones in suspected biliary pancreatitis: comparison of MRCP, ERCP, and intraductal US,” *American Journal of Gastroenterology*, vol. 100, no. 5, pp. 1051–1057, 2005.

[16] S. Tsuchiya, T. Tsuyuguchi, Y. Sakai et al., “Clinical utility of intraductal US to decrease early recurrence rate of common bile duct stones after endoscopic papillotomy,” *Journal of Gastroenterology and Hepatology*, vol. 23, no. 10, pp. 1590–1595, 2008.

[17] S. N. Stavropoulos, A. Larghi, E. Verna, P. Battezzati, and P. Stevens, “Intraductal ultrasound for the evaluation of patients with biliary strictures and no abdominal mass on computed tomography,” *Endoscopy*, vol. 37, no. 8, pp. 715–721, 2005.

[18] D. Domagk, J. Wessling, P. Reimer et al., “Endoscopic retrograde cholangiopancreatography; intraductal ultrasonography, and magnetic resonance cholangiopancreatography in bile duct strictures: a prospective comparison of imaging diagnostics with histopathological correlation,” *American Journal of Gastroenterology*, vol. 99, no. 9, pp. 1684–1689, 2004.

[19] C. C. Lee, C. Y. Wu, and G. H. Chen, “What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma?” *Journal of Gastroenterology and Hepatology*, vol. 17, no. 9, pp. 1015–1020, 2002.

[20] T. Kuroki, Y. Tajima, and T. Kanematsu, “Hepatolithiasis and intrahepatic cholangiocarcinoma: carcinogenesis based on molecular mechanisms,” *Journal of Hepato-Biliary-Pancreatic Surgery*, vol. 12, no. 6, pp. 463–466, 2005.

[21] F. Holzinger, K. Z’graggen, and M. W. Büchler, “Mechanisms of biliary carcinogenesis: a pathogenetic multi-stage cascade towards cholangiocarcinoma,” *Annals of Oncology*, vol. 10, supplement 4, pp. 122–126, 1999.

[22] K. Hanada, A. Tsuchida, and G. Kaijyama, “Cellular kinetics and gene mutations in gallbladder mucosa with an anomalous junction of pancreaticobiliary duct,” *Journal of Hepato-Biliary-Pancreatic Surgery*, vol. 6, no. 3, pp. 223–228, 1999.

[23] Y. Matsumoto, H. Fujii, J. Itakura et al., “Pancreaticobiliary maljunction: pathophysiological and clinical aspects and the impact on biliary carcinogenesis,” *Langenbecks Archives of Surgery*, vol. 388, no. 2, pp. 122–131, 2003.